This content is intended for U.S. physicians only.

Zephyr University: 
Professional Education for Zephyr Valve Treating Physicians

Have you been limited in your treatment options for patients suffering from advanced COPD/emphysema? Until recently, there have been limits on what medications and supplemental oxygen could deliver without resorting to surgical treatments.

The Zephyr Valve is another option! Pulmonx developed the Zephyr Valve treatment as a minimally-invasive lung volume reduction procedure that reduces hyperinflation and gas trapping in patients with emphysema.

Zephyr Valve therapy can benefit:

  • Patients who are not responding to optimal medical management
  • Patients with homogeneous or heterogeneous emphysema
  • Patients with upper lobe or lower lobe predominant emphysema
  • Patients who may not qualify for more invasive procedures such as lung volume reduction surgery or transplant

Already have login information?

Login to Zephyr University

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

United States Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.
Caution: Federal law restricts this device to sale by or on the order of a physician.
International Brief Statement: The Zephyr® Endobronchial Valve is an implantable bronchial valve intended to control airflow in order to improve lung functions in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; Evidence of active pulmonary infection; Patients with known allergies to Nitinol (nickeltitanium) or its constituent metals (nickel or titanium); Patients with known allergies to silicone; Patients who have not quit smoking. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Privacy Preference Center

Privacy Preferences